Analysts Are Upgrading Vera Therapeutics, Inc. (NASDAQ:VERA) After Its Latest Results

Vera Therapeutics, Inc. (NASDAQ:VERA) just released its third-quarter report and things are looking bullish. Revenues of US$10m beat estimates by a substantial 209% margin. Unfortunately, Vera Therapeutics also reported a statutory loss of US$1.30 per share, which at least was smaller than the analysts expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Taking into account the latest results, the most recent consensus for Vera Therapeutics from eleven analysts is for revenues of US$247.1m in 2027. If met, it would imply a substantial 2,304% increase on its revenue over the past 12 months. Losses are predicted to fall substantially, shrinking 32% to US$3.93. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$233.8m and losses of US$4.23 per share in 2027. It looks like there's been a modest increase in sentiment in the recent updates, with the analysts becoming a bit more optimistic in their predictions for both revenues and losses per share.

Check out our latest analysis for Vera Therapeutics

Despite these upgrades,the analysts have not made any major changes to their price target of US$73.00, implying that their latest estimates don't have a long term impact on what they think the stock is worth. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic Vera Therapeutics analyst has a price target of US$100.00 per share, while the most pessimistic values it at US$29.00. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Vera Therapeutics' rate of growth is expected to accelerate meaningfully, with the forecast 12x annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 109% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 22% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Vera Therapeutics to grow faster than the wider industry.

The Bottom Line

The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. The consensus price target held steady at US$73.00, with the latest estimates not enough to have an impact on their price targets.

With that in mind, we wouldn't be too quick to come to a conclusion on Vera Therapeutics. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Vera Therapeutics analysts - going out to 2028, and you can see them free on our platform here.

Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.